Media.Player

GABAA receptor modulators for the treatment of bronchoconstrictive diseases

Summary

This technology describes GABAA receptor modulators that both relax airway smooth muscle and attenuate inflammation to treat bronchoconstrictive diseases.

Technology Benefits

Selective for specific GABAA receptor subunitsReduced potential for CNS effectsFewer side effects compared to corticosteroidsMultiple delivery routesReduces inflammation and relaxes smooth muscle in the lung

Technology Application

Asthma treatmentReducing lung inflammationTreatment for chronic obstructive pulmonary diseaseTreatment of other bronchoconstrictive diseases

Detailed Technology Description

None

*Abstract

None

*Inquiry

Sara GusikColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU13064

*Principal Investigator

*Publications

Forkuo GS, Guthrie ML, Yuan NY, Nieman AN, Kodali R, Jahan R, Stephen MR, Yocum GT, Treven M, Poe MM, Li G, Yu OB, Hartzler BD, Zahn NM, Ernst M, Emala CW, Stafford DC, Cook JM, Arnold LA. “Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma Treatments” Mol Pharm. 2016 Jun 6; 13(6): 2026-38.Yocum GT, Gallos G, Zhang Y, Jahan R, Stephen MR, Varagic Z, Puthenkalam R, Ernst M, Cook JM, Emala CW. “Targeting the γ-Aminobutyric Acid A Receptor α4 Subunit in Airway Smooth Muscle to Alleviate Bronchoconstriction” Am J Respir Cell Mol Biol. 2016 Apr; 54(4): 546-53.Gallos G, Yocum GT, Siviski ME, Yim PD, Fu XW, Poe MM, Cook JM, Harrison N, Perez-Zoghbi J, Emala CW Sr. “Selective targeting of the α5-subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handling” Am J Physiol Lung Cell Mol Physiol. 2015 May 1; 308(9): L931-42.Gallos G, Yim P, Chang S, Zhang Y, Xu D, Cook JM, Gerthoffer WT, Emala CW Sr. “Targeting the restricted α-subunit repertoire of airway smooth muscle GABAA receptors augments airway smooth muscle relaxation” Am J Physiol Lung Cell Mol Physiol. 2012 Jan 15; 302(2): L248-56.Tech Ventures Reference:IR CU13064Licensing Contact: Sara Gusik

Country/Region

USA